comparemela.com

Latest Breaking News On - Branded pharmaceuticals - Page 7 : comparemela.com

ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter.

Canada
Dublin
Ireland
Canadian
Blaise-coleman
Prnewswire-endo-international
Branded-pharmaceuticals
Company-net-debt-leverage-ratio
Paladin-labs-inc
Linkedin
Generic-pharmaceuticals
Endo-investor-relations-department

Endo International plc: ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

DUBLIN, May 5, 2022 /PRNewswire/ Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial

Canada
Dublin
Ireland
Canadian
Blaise-coleman
Prnewswire-endo-international
Branded-pharmaceuticals
Company-net-debt-leverage-ratio
Paladin-labs-inc
Linkedin
Generic-pharmaceuticals
Endo-investor-relations-department

ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

DUBLIN, May 5, 2022 /PRNewswire/ Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2.

Canada
Dublin
Ireland
Canadian
Blaise-coleman
Prnewswire-endo-international
Branded-pharmaceuticals
Paladin-labs-inc
Linkedin
Company-net-debt-leverage-ratio
Generic-pharmaceuticals
Endo-investor-relations-department

ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter.

Canada
Dublin
Ireland
Canadian
Blaise-coleman
Prnewswire-endo-international
Branded-pharmaceuticals
Company-net-debt-leverage-ratio
Paladin-labs-inc
Linkedin
Generic-pharmaceuticals
Endo-investor-relations-department

Endo International plc (NASDAQ:ENDP) Receives Consensus Rating of "Hold" from Analysts

Shares of Endo International plc (NASDAQ:ENDP – Get Rating) (TSE:ENL) have been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation […]

United-states
Piper-sandler
Sterling-investment-advisors-ltd
Carolina-wealth-advisors
Zacks-investment-research
Nasdaq
Nisa-investment-advisors
Endo-international
Its-branded-pharmaceuticals
Endo-international-get-rating
Barclays
Campbell-co-investment-adviser

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.